58th European Association for the Study of Diabetes (EASD) Annual Meeting

Stockholm, Sweden 20 September 2022 - 23 September 2022

ESSENTIAL: Ezetimibe plus statin reduces liver fat

31 Oct 2022 by

Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.

31 Oct 2022

Hysterectomy tied to increased diabetes risk

21 Oct 2022 by

Undergoing a hysterectomy, particularly at a young age, may be associated with an increased risk of developing diabetes, according to a study from France presented at EASD 2022.

21 Oct 2022

Beta-blocker shows potential for diabetic foot ulcers

20 Oct 2022 by

A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).

20 Oct 2022

Sotagliflozin may offer cardiorenal protection for adults with T1D

13 Oct 2022 by

Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).

13 Oct 2022

Triple-drug combo reduces HbA1c in T2D

12 Oct 2022 by

Adding evogliptin, a novel dipeptidyl peptidase-4 inhibitor, to dapagliflozin and metformin significantly reduced HbA_1c level in patients with uncontrolled type 2 diabetes (T2D), according to a study presented at EASD 2022.

12 Oct 2022

Does age at diagnosis affect diabetes outcomes?

09 Oct 2022 by

Individuals who are diagnosed with type 2 diabetes (T2D) at age ≤40 years have a greater risk of cardiovascular disease (CVD) and mortality than same-aged individuals without T2D or individuals diagnosed with T2D in later life, according to a study from Korea presented at EASD 2022.

09 Oct 2022

Tirzepatide confers renal protection in patients with T2D

05 Oct 2022 by

Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.

05 Oct 2022